This is a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with Selgantolimod (SLGN). Intensive PK sampling will be conducted in the first 12 participants who enroll into the study.
The hypothesis is that administration of the oral toll-like receptor (TLR) 8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses. Therefore, this study will evaluate 3 mg SLGN dosing among virally suppressed individuals with both HIV and CHB.
Expected Impact: To inform global CHB treatment guidelines, where we have SLGN approved for treatment of chronic hepatitis B among HIV-infected individuals.
